Patent advice regarding an IPO for Life Science company

BioArctic is a biopharmaceutical company focusing on innovative treatments that help patients with central nervous system diseases

BioArctic is a Swedish research-based biopharmaceutical company that develops antibody-based disease modifying treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company also develops an innovative treatment concept for complete spinal cord injuries.

We assisted BioArctic with patent advice in connection to the IPO

Our patent consultant Tomas Lundquist, who has worked with BioArctic since 2014, is continuously working on building and managing BioArctic’s strategically important patent portfolio.

Prior to BioArctic’s Initial Public Offering, Tomas assisted BioArctic with analyzes of the company’s patent situation. The material highlighted all relevant aspects from a patent perspective and was used as input for various Due Diligence analyzes. During the Due Diligence procedure, Tomas assisted BioArctic by answering patent-related questions posed by parties who conducted the Due Diligence work. Tomas also assisted with patent-related information for the investment documentation used by BioArctic in presentations for potential investors.

In an IPO, the stock auditor also places high demands on the company at hand, where some parts concern patent-related issues, such as ownership and risks associated with the patent portfolio. Tomas also assisted BioActic with these matters.

BioArctic was the largest Swedish listing in Life Science since 2000

BioArtics was listed on Nasdaq Stockholm Mid Cap on October 12, 2017. The company’s market value was SEK 2.11 billion (over 200 million Euro) based on the subscription price. In connection to the IPO, Tomas was specially invited as a key consultant and joined BioArctic to celebrate their success on site at Nasdaq.

 

For BioArctic, patent-related issues are of major strategic significance for the company’s long-term sustainability. Therefore, we invest a lot of resources and we focus strongly on managing these important tasks in the best possible way, says Gunilla Osswald, CEO of BioArctic AB.

"For BioArctic, patent-related issues are of major strategic significance for the company's long-term sustainability. Therefore, we invest a lot of resources and we focus strongly on managing these important tasks in the best possible way."

Date

Oct 2017

Client

BioActic AB

Branch

Life Science

Contact(s)

Tomas Lundquist

Partner

European Patent Attorney

Authorised Patent Attorney (SE)

+46 8 729 91 45

tomas.lundquist@groth.eu

Top

Contact us

Countries & Contacts

  • Jordglob

    Stockholm

    Headquarter

    Groth & Co KB
    Box 6107
    SE-102 32 STOCKHOLM

    Visiting address:
    Birger Jarlsgatan 57 B, 113 56 Stockholm
    SWEDEN
    Telephone: +46 8 729 91 00
    Email: info@groth.eu
    Fax: +46 8 31 67 67

    Show on map

  • Jordglob

    Alicante

    Groth & Co KB
    Avda. De Aguilera 19-1 B
    E-03007 ALICANTE
    SPAIN
    Telephone: +34 96 592 04 55
    Email: info@groth.eu
    Fax: +34 96 592 05 03

    Show on map

  • Jordglob

    Munich

    Groth GmbH
    Rosenkavalierplatz 4
    D-81925 MUNICH
    GERMANY
    Telephone: +49 89 982 952 63
    Email: info@groth.eu
    Fax: +49 89 982 952 65

    Show on map

  • Jordglob

    Shanghai

    Groth & Co KB
    378 WuKang Road, Office 303
    200031 SHANGHAI
    CHINA
    Telephone: +86 1361 180 4064
    Email: info@groth.eu

    Show on map